Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 14, 2023 08:30 ET | Source: Albireo Pharma, Inc.

FDA Grants June 15, 2023 PDUFA Date to Albireo for Bylvay® in Alagille Syndrome

Bylvay (odevixibat) granted Priority Review by U.S. FDAASSERT study demonstrated efficacy of Bylvay in pruritus, bile acids and sleep with a low drug-related diarrhea rate in Alagille patientsApproval...
December 20, 2022 16:30 ET | Source: Albireo Pharma, Inc.

Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today...
December 19, 2022 08:30 ET | Source: Albireo Pharma, Inc.

Albireo Submits Bylvay® Alagille Syndrome Regulatory Filings to FDA and EMA

- Gold standard Phase 3 ASSERT study supports supplementary filings in the U.S. and EU - ASSERT study demonstrated efficacy of Bylvay (odevixibat) in pruritus, bile acids and sleep with a low...
December 06, 2022 16:30 ET | Source: Albireo Pharma, Inc.

Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today...
December 06, 2022 08:30 ET | Source: Albireo Pharma, Inc.

Albireo Appoints Paul Streck, M.D., as Chief Medical Officer & Craig Hopkinson, M.D., to Board of Directors

– Dr. Craig Hopkinson, currently EVP of Research & Development and Chief Medical Officer at Alkermes, brings strong global orphan drug development expertise – Dr. Paul Streck, former Chief...
November 30, 2022 08:30 ET | Source: Albireo Pharma, Inc.

Inscription sur la liste des médicaments remboursables aux assurés sociaux de Bylvay® (odevixibat) pour les patients atteints de PFIC 1 & 2 (à l’exception du sous- type BSEP3 de la PFIC 2) chez les patients âgés de 6 mois et plus

BOSTON, 30 nov. 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq : ALBO), une société spécialisée dans les maladies rares qui développe de nouveaux modulateurs d'acides biliaires pour traiter...
November 30, 2022 08:30 ET | Source: Albireo Pharma, Inc.

Reimbursed Access to Bylvay® (odevixibat) Approved in France for Patients with PFIC 1 & 2

BOSTON, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today...
November 09, 2022 08:30 ET | Source: Albireo Pharma, Inc.

Albireo to Participate in Jefferies London Healthcare Conference

BOSTON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today...
November 08, 2022 16:01 ET | Source: Albireo Pharma, Inc.

Albireo Reports Q3 2022 Financial Results and Business Update

Bylvay® (odevixibat) Q3 2022 PFIC net revenue of $7.5 million, September YTD 2022 $18.1 millionNew disease modification and native liver survival data with Bylvay in PFIC patients presented at AASLD...
November 07, 2022 08:30 ET | Source: Albireo Pharma, Inc.

Bylvay® (odevixibat) Data Presented at AASLD The Liver Meeting® 2022, Demonstrating Native Liver Survival in Children Across PFIC Types

Early, rapid, and sustained efficacy across wide range of patients with evidence of disease modificationLong-term preservation of native liver in PFIC, improvements in pruritus, bile acids, and...